Autologous vs. Allogeneic Cell Therapy: Key Differences in Regulatory Expectations

By Alicja Fiedorowicz, MSc, Associate Director, CMC at Allucent

The success of cell therapy programs depends on a clear understanding of the differences between autologous and allogeneic treatments, from their respective development challenges to the regulatory frameworks governing their clinical use. Autologous cell therapies use the patient’s own cells to create a personalized treatment with minimal risk of immune rejections. In contrast, allogeneic cell therapies utilize donor cells to develop an off-the-shelf and scalable product, however they require immunosuppressive measures or genetic and/or biochemical modifications to enhance compatibility and reduce the risk of immune rejection.

Currently, most genetically modified T cell therapies are autologous, with products primarily approved for rare disease and oncological indications. Well-known examples include CAR T therapies like Yescarta (axicabtagene ciloleucel) or Kymriah (tisagenlecleucel), which use a patient’s own cells, genetically modified to target and destroy tumour cells. Additionally, the recent FDA approval of Encelto (revakinagene taroretcel), through a BLA, following a Regenerative Medicine Advanced Therapy (RMAT) designation, marks a significant milestone for genetically modified allogeneic therapies, paving the way for off-the-shelf treatment options for a broader range of patients. Encelto is an allogeneic retinal pigment epithelium cell therapy indicated for ophthalmic use.

Regulatory Requirements for Cell Therapies

The regulatory landscape for autologous and allogeneic cell therapies is evolving, with distinct guidelines governing eligibility of donor material, manufacturing, safety, and clinical use to ensure product consistency, efficacy, and patient safety. Both types of therapies are subject to 21 CFR Part 1271 part C, which establishes current good tissue practices to prevent contamination and ensure product integrity. Health authorities also emphasize the importance of comprehensive traceability measures, such as chain-of-custody, to avoid product mix-ups and ensure patient safety, as explained in the EMA’s Guideline On Human Cell-Based Medicinal Products. Given that autologous therapies are individualized, any failure in tracking or documentation could result in the wrong product being administered to a patient, potentially leading to serious adverse effects. In a guidance released in 2015, Considerations for the Design of Early-Phase Clinical Trials of Cellular and Gene Therapy Products, the FDA recommends that sponsors incorporate at least two unique identifiers on the labeling, such as a donor identification number or a batch number to mitigate this risk. These identifiers serve as key tools for cross-checking records at every stage of the process, from collection to manufacturing and delivery, ensuring that the correct product reaches the right patient.

Autologous therapies face unique regulatory challenges related to manufacturing, supply chain logistics, and traceability. Each batch of source material is limited to a pool of cells from a single patient, which necessitates strict quality control and leaves no margin for handling errors. Timely processing is also critical, as autologous therapies must be manufactured and administered within a short turnaround window to align with the patient’s treatment schedule and often declining health. Moreover, scalability is not realistically achievable, as each batch is tailored for a single patient and cannot be used for other patients. Donor eligibility requirements are generally less strict since the donor and recipient are the same individual. Under 21 CFR §1271.50 and §1271.90, sponsors must confirm that the patient is the intended donor and is suitable to donate but are not required to conduct extensive infectious disease testing. However, autologous products must still meet traceability and sterility requirements, as explained in the FDA guidance document Eligibility Determination for Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) 

Allogeneic Cell Therapy: Regulatory and Manufacturing Considerations

On the other side, allogeneic therapies are manufactured from cells obtained from healthy individuals and have the advantage of being used for the treatment of multiple patients. This offers the potential for standardized therapy, scalable manufacturing, and immediate product availability (often referred to as “off-the-shelf”). Clinical trials in this area are rapidly growing, particularly for allogeneic CAR T and NK cell therapies. Additionally, a benefit of allogeneic therapies is the overall fitness and functional capacity of cells obtained from healthy donors compared to cells from patients suffering from severe or chronic conditions, potentially leading to more effective treatments. However, these therapies face additional regulatory scrutiny regarding donor eligibility. Sponsors must perform comprehensive donor screening and testing, including detailed medical history reviews, physical examinations, and laboratory testing, in order to minimize the risk of transmitting infectious agents and ensure product safety. An additional challenge with allogeneic therapies is the risk of graft-versus-host disease (GvHD), where donor cells may trigger an immune response against the recipient’s tissues. This risk requires careful product design strategies, such as modifying the cells to reduce their immunogenic potential and prevent unwanted immune reactions.

Emerging Regulatory Trends in Cell Therapy Development

Health authorities are continuously updating guidelines to better address the distinct challenges of each therapy type, particularly those of allogeneic therapies, which are likely to represent the next wave of approved CGT products. In April 2024, the FDA released a draft guidance, Safety Testing of Human Allogeneic Cells Expanded for Use in Cell-Based Medical Products, which also included requirements for categorizing cell products based on expansion levels, reagent use, and intended recipient numbers (extensively expanded cells, limited expansion cells, and those administered to a few individuals). This approach ensures that safety testing is tailored to the specific characteristics of each cell product, addressing risks such as microbial contamination and genomic alterations based on the extent of cell expansion.

Given the complexities inherent in both autologous and allogeneic therapies, engaging in pre-IND meetings and seeking early Scientific Advice from health authorities is essential for sponsors to ensure alignment with evolving guidelines and regulatory expectations. This proactive approach is key to the early mitigation of potential risks and reduces the likelihood of program delays due to non-compliance.

Strategic Considerations for Cell Therapy Development

In summary, while autologous therapies currently dominate due to their personalized nature and proven clinical successes, the field of allogeneic therapies is maturing. Some companies are adopting both approaches to leverage the strengths of each, with ongoing clinical trials reflecting an industry keen to bring scalable, off-the-shelf solutions to market without sacrificing patient safety. The differences between autologous and allogeneic therapies are significant and have important implications for product labeling, manufacturing strategies, and regulatory compliance, all of which play a crucial role in shaping overall development strategies.

For both autologous and allogeneic products, implementing robust quality systems, engaging early with health authorities, and leveraging advanced tracking technologies are key strategies for navigating the complexities of cell therapy development and ensuring successful regulatory approval.